Categories: DeliveryDrugTechnology
NEUWAY Pharma is committed to bringing transformative neuropharmaceuticals across the blood-brain barrier through its EnPC®, the drug delivery technology based on a natural derived protein capsule. In addition to advancing its proprietary pipeline, the company aims to be a partner of choice in particular for antibody and mRNA drug developers stymied by the hurdles of delivering these and other drug modalities into the brain and CNS tissue.
Investors 1
Funding Rounds 2
| Date | Series | Amount | Investors |
| 07.06.2016 | Grant | $3.35M | - |
| 27.05.2014 | Series A | $3.68M | - |
Mentions in press and media 2
| Date | Title | Description |
| 07.06.2016 | NEUWAY Awarded €2.95M Grant | NEUWAY Receives €2.95 Million BMBF Grant for Advancing CNS Drug Delivery Platform. CLICK FOR MORE. |
| 27.05.2014 | Neuway Pharma Raises €2.7M in Series A Financing | Neuway Pharma GmbH, a Bonn, Germany-based company that focuses on the preclinical and clinical development of innovative therapeutics for treatment of orphan brain diseases, raised €2.7m in Series A financing.
The round was led by Wellingto... |
Reviews 0
